(Q41428184)

30 September 2017

1 reference

title

New therapies for chronic hepatitis B. (English)

1 reference

30 September 2017

Hoofnagle JH

1

1 reference

30 September 2017

Lau D

series ordinal

2

1 reference

30 September 2017

publication date

1 January 1997

1 reference

Journal of Viral Hepatitis

30 September 2017

published in

1 reference

30 September 2017

volume

4 Suppl 1

1 reference

30 September 2017

page(s)

41-50

1 reference

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Controlled clinical trial of acyclovir in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Suramin treatment for chronic active hepatitis B--toxic and ineffective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Foscarnet therapy in chronic hepatitis B virus E antigen carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Therapy of chronic hepatitis B with a 6-month course of ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Hepatitis B reactivation after lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Inhibition of duck hepatitis B virus replication by purine 2',3'-dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Hepatitis B virus immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

Characterization of hepatitis B virus core mutants that inhibit viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1997.TB00159.X

10.1111/J.1365-2893.1997.TB00159.X

21 January 2018

Identifiers

DOI

1 reference

30 September 2017

1 reference